Eli Lilly Lowers Cash Price for Weight-Loss Drug Zepbound
Eli Lilly cuts prices for cash buyers of Zepbound, impacting pharmaceutical pricing and payer coverage dynamics.
Rising Payer Denials and Delays Challenge ASC Revenue Cycles
ASCs face increasing delays and denials from payers impacting revenue cycles. Increased scrutiny on device/pharma claims and contract carve-outs prompt ASC contract renegotiations amid Medicare Advantage changes.
Elevance Health Shows Strong Medicare Advantage Management and Carelon Growth
Elevance Health outperforms competitors by managing Medicare Advantage costs effectively and driving robust growth in its Carelon segment, bolstering its 2025 outlook and earning a Strong Buy rating with growth potential.